EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Sep 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-09-06

Reporting Person: Mazzo David J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-06	Employee Stock Option (right to buy)	$2.32	A	1667	Acquired	2028-09-06	Common Stock (1667)	Direct
2018-09-06	Deferred Stock Units	$	A	417	Acquired		Common Stock (417)	Direct

Footnotes

F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.